LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria

    Florian Kurth / Tilman Lingscheid / Florian Steiner / Miriam S. Stegemann / Sabine Bélard / Nikolai Menner / Peter Pongratz / Johanna Kim / Horst von Bernuth / Beate Mayer / Georg Damm / Daniel Seehofer / Abdulgabar Salama / Norbert Suttorp / Thomas Zoller

    Emerging Infectious Diseases, Vol 22, Iss 8, Pp 1381-

    2016  Volume 1386

    Abstract: Episodes of delayed hemolysis 2–6 weeks after treatment of severe malaria with intravenous artesunate have been described. We performed a prospective observational study of patients with uncomplicated malaria to investigate whether posttreatment ... ...

    Abstract Episodes of delayed hemolysis 2–6 weeks after treatment of severe malaria with intravenous artesunate have been described. We performed a prospective observational study of patients with uncomplicated malaria to investigate whether posttreatment hemolysis also occurs after oral artemisinin-based combination therapy. Eight of 20 patients with uncomplicated malaria who were given oral artemisinin-based combination therapy met the definition of posttreatment hemolysis (low haptoglobin level and increased lactate dehydrogenase level on day 14). Five patients had hemolysis persisting for 1 month. Patients with posttreatment hemolysis had a median decrease in hemoglobin level of 1.3 g/dL (interquartile range 0.3–2.0 g/dL) in the posttreatment period, and patients without posttreatment hemolysis had a median increase of 0.3 g/dL (IQR −0.1 to 0.7 g/dL; p = 0.002). These findings indicate a need for increased vigilance for hemolytic events in malaria patients, particularly those with predisposing factors for anemia.
    Keywords malaria ; uncomplicated malaria ; Plasmodium falciparum ; parasites ; hemolysis ; artemisinin ; Medicine ; R ; Infectious and parasitic diseases ; RC109-216
    Language English
    Publishing date 2016-08-01T00:00:00Z
    Publisher Centers for Disease Control and Prevention
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: A proteomic survival predictor for COVID-19 patients in intensive care.

    Vadim Demichev / Pinkus Tober-Lau / Tatiana Nazarenko / Oliver Lemke / Simran Kaur Aulakh / Harry J Whitwell / Annika Röhl / Anja Freiwald / Mirja Mittermaier / Lukasz Szyrwiel / Daniela Ludwig / Clara Correia-Melo / Lena J Lippert / Elisa T Helbig / Paula Stubbemann / Nadine Olk / Charlotte Thibeault / Nana-Maria Grüning / Oleg Blyuss /
    Spyros Vernardis / Matthew White / Christoph B Messner / Michael Joannidis / Thomas Sonnweber / Sebastian J Klein / Alex Pizzini / Yvonne Wohlfarter / Sabina Sahanic / Richard Hilbe / Benedikt Schaefer / Sonja Wagner / Felix Machleidt / Carmen Garcia / Christoph Ruwwe-Glösenkamp / Tilman Lingscheid / Laure Bosquillon de Jarcy / Miriam S Stegemann / Moritz Pfeiffer / Linda Jürgens / Sophy Denker / Daniel Zickler / Claudia Spies / Andreas Edel / Nils B Müller / Philipp Enghard / Aleksej Zelezniak / Rosa Bellmann-Weiler / Günter Weiss / Archie Campbell / Caroline Hayward

    PLOS Digital Health, Vol 1, Iss 1, p e

    2022  Volume 0000007

    Abstract: Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such as SOFA and APACHE II scores show only limited ... ...

    Abstract Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such as SOFA and APACHE II scores show only limited performance for predicting the survival of severely ill COVID-19 patients. Additional tools are also needed to monitor treatment, including experimental therapies in clinical trials. Comprehensively capturing human physiology, we speculated that proteomics in combination with new data-driven analysis strategies could produce a new generation of prognostic discriminators. We studied two independent cohorts of patients with severe COVID-19 who required intensive care and invasive mechanical ventilation. SOFA score, Charlson comorbidity index, and APACHE II score showed limited performance in predicting the COVID-19 outcome. Instead, the quantification of 321 plasma protein groups at 349 timepoints in 50 critically ill patients receiving invasive mechanical ventilation revealed 14 proteins that showed trajectories different between survivors and non-survivors. A predictor trained on proteomic measurements obtained at the first time point at maximum treatment level (i.e. WHO grade 7), which was weeks before the outcome, achieved accurate classification of survivors (AUROC 0.81). We tested the established predictor on an independent validation cohort (AUROC 1.0). The majority of proteins with high relevance in the prediction model belong to the coagulation system and complement cascade. Our study demonstrates that plasma proteomics can give rise to prognostic predictors substantially outperforming current prognostic markers in intensive care.
    Keywords Computer applications to medicine. Medical informatics ; R858-859.7
    Subject code 616
    Language English
    Publishing date 2022-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top